INOVIO PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.1 | $0.2 | $0.8 | $10.3 | $1.8 |
| Operating income | -$86.8 | -$112.4 | -$143.9 | -$267.6 | -$301.2 |
| Net income | -$84.9 | -$107.3 | -$135.1 | -$279.8 | -$303.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$88.9 | -$104.6 | -$124.7 | -$217.2 | -$216.9 |
Shares outstanding 103.4M · Free float 98.9%
Annual filing data through FY ended December 31, 2025; float as of October 27, 2026.
Inovio Posts $49.2 Million Loss After VOCERYQ Approval